Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 292

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 292
---
 Company’s current shareholders have in the Business Combination?” for a description of other benefits of the Business Combination to OmnigenicsAI and its affiliates.                         |     | OmnigenicsAI has and continues to incur significant fees and expenses associated with completing the Business Combination and OmnigenicsAI’s management has invested substantial time and effort to complete the Business Combination as well as the risks that the benefits sought to be achieved by the Business Combination might not be achieved fully or may not be achieved within the expected timeframe and that completion of the Business Combination is conditioned on satisfaction of certain closing conditions that are not within OmnigenicsAI’s control. |

136 Interests of APx’s Directors and Officers in the Business Combination See “ Questions and Answers About the Business Combination and the Special Meeting — What interests do our Initial Shareholders, current officers, directors and advisors, and the Company’s current shareholders have in the Business Combination?” Regulatory Approvals Required for the Business Combination Non -U.S. regulatory bodies and U.S. state attorneys general could take action under other applicable regulatory laws as they deem necessary or desirable in the public interest, including, without limitation, seeking to enjoin or otherwise prevent the completion of the Business Combination or permitting completion subject to regulatory conditions. Private parties may also seek to take legal action under regulatory laws under some circumstances. There can be no assurance that a challenge to the Business Combination on antitrust grounds will not be made or, if such a challenge is made, that it would not be successful. APx and the Company are not aware of any other regulatory approvals in the United States and Cayman Islands or elsewhere required for the consummation of the Business Combination. Litigation Relating to the Business Combination There have been no proceedings brought against APx in relation to the Business Combination or the Business Combination Agreement. Listing of Company Shares Approval of the listing on Nasdaq of the Company Shares to be issued in the Business Combination, subject to official notice of issuance, is a condition to each party’s obligation to complete the Business Combination. Accounting Treatment of the Business Combination OmnigenicsAI will account for the Business Combination as a capital reorganization in accordance with IFRS as issued by the IASB. Under this method of accounting, APx will be treated as the “acquired” company for financial reporting purposes and OmnigenicsAI will be the accounting “acquirer.” This determination was primarily based on the assumptions that OmnigenicsAI’s shareholders will hold a majority of the voting power of the Combined Company, OmnigenicsAI’s operations